Welcome to our dedicated page for Charles Riv Labs Intl SEC filings (Ticker: CRL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Charles River Laboratories International, Inc. filings document the company’s operating results, material events, governance matters, and capital-structure disclosures as a New York Stock Exchange-listed issuer with common stock trading under CRL. Form 8-K reports cover quarterly and annual financial results, guidance, share repurchase activity, completed portfolio changes, conference disclosures, and executive appointment and compensation matters.
Proxy materials describe shareholder voting matters, board elections, executive compensation, equity incentive plans, and auditor ratification. The filing record also reflects disclosure categories tied to the company’s drug discovery and development services, including segment performance for Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions, along with forward-looking risk language and compliance matters.
Form 144 filing for Charles River Laboratories International, Inc. (CRL) discloses a planned sale of 4,000 common shares through Merrill Lynch, valued at $550,000. The filer expects the transaction to occur on or about 06/23/2025. Total shares outstanding are reported at 49,115,712, so the proposed sale represents roughly 0.008% of the public float. The shares being sold were acquired on 06/02/2025 via an open-market purchase and will be settled for cash. No prior sales were reported in the past three months, and the form contains no remarks indicating special circumstances. The identity of the filer, their relationship to CRL, and any 10b5-1 plan details were not provided.
The filing is a routine notice of intent required under Rule 144 and does not, by itself, finalize the sale. Given the relatively small size versus market capitalization and the absence of additional context, the disclosure is likely to have limited market impact.